The 15th International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of national practicing oncologists, advanced nurse practitioners and physician assistants, nurses, residents, fellows, and the Chicago academic community that includes five academic centers. This year’s program offered in May 2018 represents the 15th IUCLS.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. The format of the meeting includes a combination of expert presentations, interactive case discussions, poster and abstract presentations, and an opportunity for question-and-answer debates. IUCLS is a two-day meeting held Friday and Saturday at the Kimpton Gray Hotel. Friday afternoon academic sessions concentrate on the scientific and translational aspects of lymphoma, while Saturday has a clinical focus. Additionally, the entire conference will be certified for nursing continuing education credits for the first time. A Friday morning session will be held that will specifically address the educational needs of nurses.
Learn more at the symposium website!
At the conclusion of this activity, participants will be able to:
Describe the evolving role of cellular therapy in lymphoma treatment;
Identify new targets and therapeutic agents in lymphoma treatment;
Recognize the appropriate circumstances in which to use different immune-oncology options for lymphoma treatment;
Evaluate how new scientific data affects the treatment of Hodgkin lymphoma;
Discuss the appropriate sequencing of agents in chronic lymphocytic leukemia (CLL) treatment based upon the latest scientific evidence;
Identify patients in need of central nervous system (CNS) lymphoma prophylaxis using the latest guidelines;
Distinguish when to employ treatments for various T-cell lymphoma histologies;
Outline how timing affects the use of CAR-T as a therapeutic option for lymphoma.
This activity has been designed for practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the other healthcare professionals interested in the treatment and diagnosis of lymphoma.
https://cme.uchicago.edu/iucls2018#group-tabs-node-course-default1
